KAI Pharmaceuticals, Inc. Initiates Phase 1 Trial of KAI-1455 for Ischemic Injury

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held biotechnology company, today announced that it has begun dosing subjects in a Phase 1 trial of KAI-1455. KAI-1455, the second compound to enter the clinic from KAI’s broad protein kinase C therapeutic platform, is being developed to prevent ischemic injury, a serious condition caused when there is an insufficient supply of blood to organs and tissues.